Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever

Journal of Infectious Diseases

Volumn 213, Issue 6, 2016, Pages 934-938

  Oestereich, Lisa ^a   Rieger, Toni ^a   Lüdtke, Anja ^a   Ruibal, Paula ^a   Wurr, Stephanie ^a   Pallasch, Elisa ^a   Bockholt, Sabrina ^a   Krasemann, Susanne ^a   Muñoz Fontela, César ^a   Günther, Stephan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

drug interaction; favipiravir; Lassa fever; mouse model; ribavirin

Indexed keywords

FAVIPIRAVIR; RIBAVIRIN; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; IC50; IC90; IN VITRO STUDY; IN VIVO STUDY; LASSA FEVER; LASSA VIRUS; LIMIT OF DETECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; VIRUS VIABILITY; ANIMAL; CHLOROCEBUS AETHIOPS; COMBINATION DRUG THERAPY; VERO CELL LINE;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG THERAPY, COMBINATION; LASSA FEVER; MICE; PYRAZINES; RIBAVIRIN; VERO CELLS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84964875979     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv522     Document Type: Article

References (15)

1. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20-6.
2. Asogun DA, Adomeh DI, Ehimuan J, et al. Molecular diagnostics for Lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. PLoS Negl Trop Dis 2012; 6:e1839.
3. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-54.
4. Mendenhall M, Russell A, Juelich T, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 2011; 55:782-7.
5. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-85.
6. McCormick JB, Walker DH, King IJ, et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 1986; 35:401-7.
7. Rieger T, Merkler D, Gunther S. Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers. PLoS One 2013; 8:e72290.
8. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-6.
9. Smee DF, Bray M, Huggins JW. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem Chemother 2001; 12:327-35.
10. Berendt RF, Walker JS, Dominik JW, Stephen EL. Response of influenza virusinfected mice to selected doses of ribavirin administered intraperitoneally or by aerosol. Antimicrob Agents Chemother 1977; 11:1069-70.
11. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:3487-93.
12. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32-41.
13. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One 2013; 8:e68347.
14. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martin V. Ribavirin can be mutagenic for arenaviruses. J Virol 2011; 85:7246-55.
15. Baranovich T, Wong SS, Armstrong J, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013; 87: 3741-51.